Literature DB >> 34244674

Perfect use versus typical use: translating outcomes in the treatment of diabetic macular oedema.

Mali Okada1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 34244674      PMCID： PMC8727575          DOI： 10.1038/s41433-021-01627-6

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  14 in total

Review 1.  Adherence of patients with diabetic macular oedema to intravitreal injections: A systematic review.

Authors:  Monique A Rose; Meri Vukicevic; Konstandina Koklanis
Journal:  Clin Exp Ophthalmol       Date:  2020-11-02       Impact factor: 4.207

2.  Treatment Patterns for Diabetic Macular Edema: An Intelligent Research in Sight (IRIS®) Registry Analysis.

Authors:  Ronald A Cantrell; Flora Lum; Yifeng Chia; Lawrence S Morse; William L Rich; Craig A Salman; Jeffrey R Willis
Journal:  Ophthalmology       Date:  2019-10-23       Impact factor: 12.079

3.  Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.

Authors:  David M Brown; Quan Dong Nguyen; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Patricio G Schlottmann; Amy Chen Rundle; Jiameng Zhang; Roman G Rubio; Anthony P Adamis; Jason S Ehrlich; J Jill Hopkins
Journal:  Ophthalmology       Date:  2013-05-22       Impact factor: 12.079

4.  Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.

Authors:  Jeffrey S Heier; Jean-François Korobelnik; David M Brown; Ursula Schmidt-Erfurth; Diana V Do; Edoardo Midena; David S Boyer; Hiroko Terasaki; Peter K Kaiser; Dennis M Marcus; Quan D Nguyen; Glenn J Jaffe; Jason S Slakter; Christian Simader; Yuhwen Soo; Thomas Schmelter; Robert Vitti; Alyson J Berliner; Oliver Zeitz; Carola Metzig; Frank G Holz
Journal:  Ophthalmology       Date:  2016-09-17       Impact factor: 12.079

Review 5.  Understanding contraceptive failure.

Authors:  James Trussell
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2009-02-14       Impact factor: 5.237

6.  Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Authors:  John A Wells; Adam R Glassman; Allison R Ayala; Lee M Jampol; Neil M Bressler; Susan B Bressler; Alexander J Brucker; Frederick L Ferris; G Robert Hampton; Chirag Jhaveri; Michele Melia; Roy W Beck
Journal:  Ophthalmology       Date:  2016-02-27       Impact factor: 12.079

7.  Diabetes in the UK: 2019.

Authors:  C A Whicher; S O'Neill; R I G Holt
Journal:  Diabet Med       Date:  2020-02       Impact factor: 4.359

8.  Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study.

Authors:  Jean-François Korobelnik; Vincent Daien; Céline Faure; Ramin Tadayoni; Audrey Giocanti-Auregan; Corinne Dot; Laurent Kodjikian; Pascale Massin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-02       Impact factor: 3.117

9.  Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).

Authors:  Kevin J Blinder; Pravin U Dugel; Sanford Chen; J Michael Jumper; John G Walt; David A Hollander; Lanita C Scott
Journal:  Clin Ophthalmol       Date:  2017-02-21

Review 10.  Systematic review: non-adherence and non-persistence in intravitreal treatment.

Authors:  Christoph Ehlken; Focke Ziemssen; Nicole Eter; Ines Lanzl; Hakan Kaymak; Albrecht Lommatzsch; Alexander K Schuster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-06-22       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.